Protalex — Technical Presentation (November 2012)
28 slides from Protalex's technical presentation, Nov 13, 2012
Slide 1: Phase 1 Study of Intravenous Staphylococcal Protein A in Rheumatoid Arthritis
Edward Bernton MD, 1 Eduard Krantz MD, 2 William Gannon MD 1 1 Protalex Inc., Summit, NJ, USA 2 Parexel Clinical Pharmacology, Bloemfontein, South Africa A Phase 1, Randomized, Double - blind, Placebo - controlled Multiple - dose Study of Intravenous Staphylococcal Protein A in Patients with Active
Slide 2: Forward Looking Statements Information
FORWARD LOOKING STATEMENTS INFORMATION Various statements made in this presentation are forward - looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward - looking statements include those which express plan, anticipation, intent, contingency, goals, target
Slide 3: Disclosures
Disclosures Study funded by Protalex Inc., Summit, NJ Drs Bernton and Gannon serve as paid consultants to Protalex Inc. Dr Krantz, country Principal Investigator for the study, is an employee of Parexel Clinical Pharmacology, contracted by Protalex Inc. to conduct the study
Slide 4: Highly purified Staphylococcal Protein A (SpA)
PRTX - 100 Highly purified Staphylococcal Protein A (SpA) 42 kDa bacterial membrane protein composed of five homologous 58 – 61 amino acid immunoglobulin binding domains – Binds to Fc region of IgG – Binds with high affinity to Fab framework region of Clade Vh3 Igs (most auto - antibodies [autoA
Slide 5: SpA immuno-adsorption column and prior Protalex Phase I studies
PRTX - 100 SpA immuno - adsorption column approved in 1999 as medical device for treatment of refractory RA – Responses after 6 – 12 weekly treatments – Often maintained for ≥10 months MOA not adsorption of autoAbs but exposure to leached SpA – 400 – 1200 μ g per Rx in returned plasma ≈5 – 15 μ
Slide 6: Phase Ib RCT in RA: Objectives
PRTX - 100 - 103 Phase Ib RCT in RA: Objectives Primary Assess safety and tolerability of IV SpA weekly x 4 doses Secondary Assess immunogenicity after ≥3 doses Determine PK and estimate of PRTX - 100 plasma exposure after first and fourth dose Determine whether a relationship exists between
Slide 7: Study Design
PRTX - 100 - 103: Study Design Sequential cohorts (ratio 8 active:2 placebo) randomized to receive 0.15, 0.45, 0.9 or 1.5 µg/kg IV Week 0 1 2 3 6 4 10 8 12 16 Dosing ACR & DAS assessments Anti - SPA ABS 90 days PK profile CBC, CHEM,U/A
Slide 8: Patient Eligibility
Patient Eligibility Key inclusion criteria: – Age ≥18 years with diagnosis of RA for ≥6 months – Active RA: ≥8 SJC; ≥10 TJC (58/60 count); hs - CRP ≥0.5 mg/dL – MTX (7.5 – 25 mg/week) for ≥3 months; stable doses ≥4 weeks – NSAIDS or low - dose prednisone (≤10 mg/day); doses stable ≥2 weeks – HCQ/C
Slide 9: Disease Activity Endpoints
Disease Activity Endpoints Primary outcome measure Number (%) of patients attaining DAS28 - CRP <3.2 = low disease activity by Week 6 Other outcome measures Absolute and percentage change from baseline of DAS28 - CRP across study timepoints (through 16 weeks) Change from baseline in Clinical D
Slide 10: Patient Disposition
Patient Disposition PRTX - 100 (μg/kg) No. of patients (%) 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) Placebo (n=8) Completed week 16 7 (87.5) 6 (75) 7 (87.5) 5 (100) 7 (87.5) Discontinued prematurely 1 (12.5) 2 (25) 1 (12.5) 0 1 (12.5) Reason for premature discontinuation: Consent withdrawal 0 0 1
Slide 11: Baseline Demographics and Disease Characteristics
Baseline Demographics and Disease Characteristics PRTX - 100 (μg/kg) Characteristic 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) Placebo (n=8) Mean age, y 51.0 54.6 46.1 47.0 46.5 Caucasian, % 50 87.5 37.5 60 50 Median disease duration, y 7.7 9.6 6.8 3.8 2.9 Mean TJC (28 joint) 20.6 15.3 13.9 15.0 16.
Slide 12: Safety: Serious Adverse Events
Safety: Serious Adverse Events SAEs: – 0.45 μ g/kg – fracture of L humerus – 0.45 μ g/kg – acute gastritis and colitis, resolved after discontinuation of meloxicam and treatment with PPI and 5 - ASA , no acute colonoscopy, no biopsy patient withdrew from study during follow - up phase – 0.9 μ g/kg
Slide 13: Common Related Treatment-Emergent AEs
Common (≥5%) Related Treatment - Emergent AEs Several were components of acute infusion reactions: included mild – moderate nausea, dizziness, muscle spasms, and flushing PRTX - 100 (μg/kg) Event, n (%) 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) Placebo (n=8) Nausea 1 (12.5) 2 (25) 2 (25) 0 0 Musc
Slide 14: Most Common Treatment-Emergent AEs
Most Common Treatment - Emergent AEs (≥12% in all PRTX - 100 group) PRTX - 100 (μg/kg) Event, n 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) All (n=29) Placebo (n=8) Headache 6 6 4 0 16 (55%) 2 (25%) RA flare 4 1 1 2 8 (28%) 1 (13%) Nausea 2 3 2 1 8 (28%) 0 Muscle spasms 1 2 3 0 6 (21%) 1 (13%) Nasoph
Slide 15: Laboratory AEs
Laboratory AEs Laboratory findings: – No trends seen in changes from baseline observed in any laboratory parameters in any treatment group – Individual clinically significant lab values included anemia, hyponatremia, hypokalemia, and lymphopenia not felt to be related to PRTX - 100
Slide 16: Acute Infusion Reactions
Acute Infusion Reactions No patients received pre - medication before treatments Three patients (1: 0.45 μg/kg; 2: 0.90 μg/kg) experienced mild to moderate infusion reactions to study drug within 5 min of dosing, all after 3 rd dose Reactions characterized by dizziness and ≥2 of the following:
Slide 17: Disease Activity: DAS28-CRP score <3.2
Disease Activity: DAS28 - CRP score <3.2 at Week 6 (primary endpoint) and Week 10 % of patients Week 6 3/29 (10%) Week 6 0/8 Week 10 6/29 (21%) Week 10 0/8
Slide 18: Disease Activity: CDAI Score by Visit (1.5 µg/kg group)
0 10 20 30 40 50 60 Baseline Wk 2 Wk 4 Wk 6 Wk 8 Wk 10 Wk 12 Wk 16 CDAI Score 1072 1074 4004 4008 5001 Disease Activity: CDAI Score by Visit (1.5 μ g/kg group)
Slide 19: Disease Activity: CDAI ≤10 (Low Disease Activity)
Disease Activity: CDAI ≤10 (Low Disease Activity) PRTX - 100 (μg/kg) CDAI ≤10, n (%) 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) Placebo (n=8) Week 2 0 0 0 0 1 (12.5%) Week 6 1 (12.5%) 0 2 (25%) 2 (40%) 1 (12.5%) Week 10 1 (12.5%) 0 2(25%) 2 (40%) 2 (25%) Any 2 consecutive visits 1 (12.5%) 1 (12.5%)
Slide 20: Immunogenicity
Immunogenicity At baseline, all patients negative for anti - drug antibodies (ADAs) 21 of 24 active - dosed patients had measurable ADA titers on day 21 No IgE Abs vs SpA using a sensitive ELISA (LLD <1 ng/mL) PRTX - 100 (μg/kg) Day 21 ADA titer * , n 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5)
Slide 21: Plasma PK Parameters after First Dose
Plasma PK Parameters after First Dose of PRTX - 100 0.9 μg/kg 1.50 μg/kg Parameter Geometric mean Min, max Geometric mean Min, max C max (ng/mL) 26.5 16, 52 51.9 42, 66 AUC (ng/mL*h) 158 18, 388 615 67, 3274 CL (mL/h/kg) 4.9 1.9, 41.6 2.1 0.42, 16.8 Vz (mL/kg) 59 39, 93 45 29, 62 t ½ (h) 8.4 1.6, 19
Slide 22: Pharmacokinetics
Pharmacokinetics The relationship of PRTX - 100 dose to C max and AUC was linear, but clearance and AUC were extremely variable within dose cohorts
Slide 23: Plasma Concentrations in Patients with or without ADAs
Patients with ADAs showed increased plasma clearance of PRTX - 100 by the fourth dose First and Fourth Dose Plasma Concentrations in Individual Patients with or without ADAs No ADAs ADA titer = 2400 0 6 12 18 24 30 36 42 48 0 4 3 2 1 Time since dose (h) Concentration (ng/mL) Day 0 Day 21 Concentra
Slide 24: Relationship Between AUC Ratio and Antibody Titer
Relationship Between the AUC (0 - t) Ratio Day 21/Day 0 and Antibody Titer Day 21 Antibody Titer AUC (0 - t) ratio day 21/day 0) 0.001 10 0.01 1 0.1 0 <400 >400
Slide 25: ADA Titers of Disease Activity Responders
Day 21 ADA Titers of Disease Activity Responders (CDAI ≤11 on 2 Visits or More) Development of ADAs did not appear to preclude a disease activity response Patient No. ADA titer PRTX - 100 dose ( μ g/kg) Responder 02 - 012 207 0.15 Yes 01 - 048 7169 0.45 Yes 01 - 031 3619 0.45 Yes 01 - 058 6848 0.9
Slide 26: Summary
Summary Highly purified SpA was well - tolerated: – 3 patients with mild to moderate infusion reactions; this did not recur with slowing the infusion rate – SpA elicited ADAs in the majority of patients but incidence or titer of ADAs was not dose - dependent. No IgE ADAs detected. – Patients with
Slide 27: Conclusions
Conclusions This pilot study demonstrated acceptable tolerability and toxicity of four weekly IV doses of PRTX - 100 up to 1.5 µg/kg There is a suggestion that PRTX - 100 has an effect on disease activity, even in patients with ADAs, which would require confirmation in a larger study. These fi
Slide 28: Investigators
Investigators Dr Eduard Krantz: Parexel International, Bloemfontein, South Africa Dr Dawie Kruger: Parexel International, George, South Africa Dr Francios Malan, Dr Reinard McPherson: Parexel International, Port Elizabeth, South Africa Dr Margare du Toit: Synexus Clinical Research Centre, Pr